Grufity logo
Grufity logo
PYXS

PYXS - Pyxis Oncology, Inc. Stock Price, Fair Value and News

$1.75+0.01 (+0.57%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

53/100

PYXS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

53/100

PYXS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

PYXS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PYXS Price Action

Last 7 days

3.6%

Last 30 days

-23.2%

Last 90 days

8.0%

Trailing 12 Months

45.8%

PYXS RSI Chart

PYXS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PYXS Valuation

Market Cap

109.3M

Price/Earnings (Trailing)

-1.34

Price/Sales (Trailing)

7.24

EV/EBITDA

-1.15

Price/Free Cashflow

-1.63

PYXS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

PYXS Fundamentals

PYXS Revenue

Rev. Growth (Qtr)

-100%

PYXS Earnings

Earnings (TTM)

-81.8M

Earnings Growth (Yr)

-10.12%

Earnings Growth (Qtr)

-28.69%

PYXS Profitability

Operating Margin

84.18%

EBT Margin

-627.94%

Return on Equity

-261.49%

Return on Assets

-127.16%

Free Cashflow Yield

-61.26%

PYXS Investor Care

Shares Dilution (1Y)

1.95%

Diluted EPS (TTM)

-1.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
20251.2M4.1M4.1M15.1M
202421.1M19.4M17.7M16.1M
20234.4M5.9M6.9M6.6M
2022---2.8M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Pyxis Oncology, Inc.

PYXS
Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEhttps://pyxisoncology.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES72

Pyxis Oncology, Inc. Frequently Asked Questions

PYXS is the stock ticker symbol of Pyxis Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Pyxis Oncology, Inc. is 109.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, PYXS's PE ratio (Price to Earnings) is -1.34 and Price to Sales (PS) ratio is 7.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PYXS PE ratio will change depending on the future growth rate expectations of investors.